Noul Inc. has developed the next generation POC (Point-Of-Care) blood testing platform for resource-limited medical facilities, clinics, and local hospitals. Noul seeks to solve global challenges that threaten human life, to discover novel solutions, and to establish a new gold standard in POC blood testing. Noul’s solution aims to improve accessibility to proper health care by integrating innovations in biology, artificial intelligence, mobile technology, robotics, and software/hardware engineering. Noul has filed over 65 global patents, conducted more than seven field clinical trials, and has research partnerships with world-class global institutions. [Mission] We explore global challenges that threaten human health and life, discover novel potential solutions, and realize those possibilities. [Goal] 1. To contribute to eliminating malaria, tb, aids and other neglected diseases through innovative diagnostic platform. 2. To proactively increase healthcare accessibility through next-generation blood diagnostics platform.
$3.1M sweet spot round size
2015
$3.1M
from 1 investors over 1 rounds
NOUL Co., Ltd. raised $3.1M on April 26, 2023
Investors: RIGHT Foundation